July 18th 2025
Being overweight or obese may lower all-cause mortality risks in non–cystic fibrosis (CF) bronchiectasis patients, while being underweight increases health complications.
July 10th 2025
Significant gaps in arthritis subtype awareness among US adults underscore the need for improved health literacy and more targeted public health efforts.
July 8th 2025
Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.
June 11th 2025
Late-breaking data reveal durable improvements in joint, skin, and quality of life outcomes with deucravacitinib.
June 6th 2025
Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape
Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models
Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape
Managing Patients With COPD: Evidence-Based Care and Optimizing Value of New and Emerging Targeted Therapies
Managed Care Approaches to Individualize Treatment of Hereditary Angioedema
From Strict Avoidance to Tailored Therapies: Transforming Food Allergy Care
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Leveraging Biologics and Immunotherapies in the Management of Food Allergies
Reflecting on the Real-World Use of Biologic Therapy in Asthma Management
Targeting Chronic Rhinosinusitis With Nasal Polyps With Biologics: Optimizing Outcomes and Reducing Health Care Burden
Emerging Treatment Options for Inflammatory Bowel Disease: A Focus on IL-23 Pathway Inhibition
Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care Approaches
The Expanding Therapeutic Landscape in IgA Nephropathy: Applying Evidence-Based Strategies and Guideline Updates for Managed Care
The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes
2 Commerce Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.